TrialJournal for immunotherapy of cancer2020

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.

Yan Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.